A phase I study of oral uracil/ftorafur (UFT) plus leucovorin and bis-acetato-ammine-dichloro-cyclohexylamine-platinum IV (JM-216) each given over 14 days every 28 days

[1]  I. Judson,et al.  Phase I and pharmacokinetic study of an oral platinum complex given daily for 5 days in patients with cancer. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  Y. Niho,et al.  Schedule‐dependent reversion of acquired cisplatin resistance by 5‐fluorouracil in a newly established cisplatin‐resistant HST‐1 human squamous carcinoma cell line , 1996, International journal of cancer.

[3]  L. Saltz,et al.  A fixed‐ratio combination of uracil and ftorafur (UFT) with low dose leucovorin. An active oral regimen for advanced colorectal cancer , 1995, Cancer.

[4]  J. Yu,et al.  Messenger RNA levels of XPAC and ERCC1 in ovarian cancer tissue correlate with response to platinum-based chemotherapy. , 1994, The Journal of clinical investigation.

[5]  D. Priest,et al.  Biochemical basis for cisplatin and 5-fluorouracil synergism in human ovarian carcinoma cells. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[6]  L. Kèlland,et al.  Biotransformation of the platinum drug JM216 following oral administration to cancer patients , 1996, Cancer Chemotherapy and Pharmacology.

[7]  N. Petrelli,et al.  A phase I and pharmacokinetic study of oral uracil, ftorafur, and leucovorin in patients with advanced cancer , 1996, Cancer Chemotherapy and Pharmacology.

[8]  T. Taguchi,et al.  [Report on nationwide pooled data and cohort investigation in UFT phase II study]. , 1987, Gan to kagaku ryoho. Cancer & chemotherapy.

[9]  W. Sadee,et al.  Activation of Ftorafue [R,S-1-(tetrahydro-2-furanyl)-5-fluorouracil] to 5-fluorouracil and gamma-butyrolactone. , 1980, Cancer research.